Aoxing Pharmaceutical Company, Inc. announced earnings results for the year ended June 30, 2013. Revenue for the year ended June 30, 2013 was $10,829,839, representing a 33% increase over the revenue realized in fiscal year 2012. The increase in revenue was mainly attributable to the increase in sales of main product, Zhongtongan, which is now being marketed for gynecological and orthopedic applications in addition to its core pediatric and stomotological market.

Sales of Zhongtongan accounted for 91% of sales during the 2013 fiscal year. The company recorded a loss from operations of $14,221,445 for the year ended June 30, 2013, approximately equal to the loss from operations of $14,548,524 recorded in fiscal 2012. Due primarily to net interest expense of $2,986,568, the company incurred a net loss of $17,290,618 for the year ended June 30, 2013, compared to a net loss of $15,877,754 for the year ended June 30, 2012.